Ravi Anand, M.D., Ph.D.
Dr. Ravi Anand is a clinician and research physician with extensive experience in the pharmaceutical industry where he has specialized in the clinical development of drugs to treat central nervous system disorders.
While at Novartis (Sandoz) from 1989-2001, Dr. Anand gained broad experience in a number of activities, including c linical development, medical and regulatory affairs and business development. From 1991 to 1997, Dr. Anand was Medical Director in charge of Clinical Research and Development at Sandoz (Novartis), where he played a major role in the clinical development of Exelon, Tileptal, Comtan and Clozapine. Dr. Anand's major achievements include primary responsibility for the development of Exelon for CNS indications, and he was responsible for Novartis' global CNS NDA filing on Exelon, and global registration of Clozaril to treat schizophrenia. More recently, as Executive Director and Head Clinical Projects, CNS, at N.V. Organon Inc. from 2001-2003,
Dr. Anand had chief responsibility for the clinical development of drugs to treat schizophrenia, depression and insomnia.
Dr. Anand received a Doctorate of Medicine at University College of Medical Sciences in New Delhi, India and further clinical training at NYU Medical Center, New York, NY.
Jeffrey Cummings, M.D.
Director, Cleveland Clinic Lou Ruvo Center for Brain Health
Rachelle Smith Doody, M.D., Ph.D.
Professor of Neurology and Effie Marie Cain Chair in Alzheimer's Disease Research, Baylor College of Medicine
P. Murali Doraiswamy, M.D.
Professor of Psychiatry and Behavioral Science
Chief, Biological Psychiatry, Duke University Medical Center
Serge Gauthier, M.D., FRCPC
Professor of Neurology and Psychiatry, Director,
McGill Centre for Studies in Aging, McGill University
Ranga Krishnan, M.B. Ch.B.
Professor and Dean
Duke NUS Graduate Medical School, Singapore
Ranga Krishnan, M.B., Ch.B., is the dean of the Duke-National University of Singapore Graduate Medical School (Duke-NUS). A native of Madras, Krishnan received his medical degree from Madras Medical College. He came to Duke in 1981 as a psychiatry resident and was appointed a faculty member in 1985. Krishnan is an internationally renowned expert in treating depression and other brain disorders of the elderly. He has written four books, more than 50 textbook chapters and more than 380 journal articles on the subjects of elderly depression, dementia, Alzheimer's disease, panic disorder, bipolar disorder in late life and obsessive-compulsive disorder, among others. In the late 1990's, he identified and described the pathology of a then little-known condition called vascular depression, in which small strokes in the mood centers of the brain give rise to a unique type of depression.
Frank LaFerla, Ph.D.
Chancellor's Professor of Neurobiology and Behavior,
Chair, Institute for Memory Impairments and Neurological Disorders
University of California, Irvine